Pomalidomide (CAS 19171-19-8) Comprehensive Guide 2025
Table of Contents
- 1. Product Specifications & Comparative Analysis
- 2. Clinical & Research Applications
- 3. Administration Protocols
- 4. Global Case Studies
- 5. Industry Adoption Metrics
- 6. Procurement Consultation
1. Product Specifications & Comparative Analysis
| Parameter | Pomalidomide (CAS 19171-19-8) | Analog Compound A | Analog Compound B |
|---|---|---|---|
| Molecular Formula | C13H11N3O4 | C14H13N3O5 | C12H10N2O3 |
| Purity | ≥99.8% | ≥98.5% | ≥97.0% |
| Storage Temperature | 2-8°C | Ambient | -20°C |
2. Clinical & Research Applications
Pomalidomide demonstrates therapeutic efficacy in:
- Relapsed/Refractory Multiple Myeloma (RRMM) treatment protocols
- Myelodysplastic Syndromes (Phase III trials)
- Immunomodulatory combination therapies
3. Administration Protocols
Standard dosage: 4mg orally on days 1-21 of 28-day cycles. Requires monitoring of:
- Neutrophil counts (weekly)
- Thrombocytopenia parameters
- Teratogenicity prevention systems
4. Global Case Studies
Case 1: European Cancer Institute (2024)
213 RRMM patients showed 63% progression-free survival rate over 18 months when combined with daratumumab.
Case 2: Johns Hopkins Oncology Center Trial
Phase II study achieved 41% overall response rate in del(17p) mutation subgroup.
5. Industry Adoption Metrics
| Manufacturer | Annual Production Capacity | Regulatory Compliance |
|---|---|---|
| PharmaCorp Global | 1,200kg | FDA, EMA, PMDA |
| OncoSolutions Ltd. | 800kg | WHO-GMP, ISO 9001 |
6. Procurement Consultation
Request current batch certifications and supply chain documentation:
Email: info@vivalr.com
Tel: (86) 15866781826



评论
目前还没有评论。